EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study results Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS) 08.04.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International